Literature DB >> 24203443

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly.

Paolo Serafini1.   

Abstract

Myeloid derived suppressor cells (MDSCs), a heterogeneous population of myeloid progenitors, are recognized as a key element in tumor escape and progression. The importance of MDSCs in human malignancies has been demonstrated in recent years, and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials. However, emerging evidence suggests that MDSCs may play a prominent role as regulator of the physiologic, the chronic, and the pathologic immune responses. This review will focus on the biology of MDSC in light of these new findings and the possible role of this myeloid population not only in the progression of the tumor but also in its initiation.

Entities:  

Mesh:

Year:  2013        PMID: 24203443     DOI: 10.1007/s12026-013-8455-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  150 in total

1.  Nitric oxide regulation of human peripheral blood mononuclear cells: critical time dependence and selectivity for cytokine versus chemokine expression.

Authors:  Sarah E Macphail; Claire A Gibney; Bernadette M Brooks; C George Booth; Brian F Flanagan; John W Coleman
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

Review 2.  Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

Authors:  V Bronte; P Serafini; E Apolloni; P Zanovello
Journal:  J Immunother       Date:  2001 Nov-Dec       Impact factor: 4.456

3.  Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells.

Authors:  M R Young; M A Wright; Y Lozano; M M Prechel; J Benefield; J P Leonetti; S L Collins; G J Petruzzelli
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

4.  Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones.

Authors:  H Gmünder; H P Eck; W Dröge
Journal:  Eur J Biochem       Date:  1991-10-01

Review 5.  Nitric oxide and the immune response.

Authors:  C Bogdan
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

6.  Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.

Authors:  K Kono; F Salazar-Onfray; M Petersson; J Hansson; G Masucci; K Wasserman; T Nakazawa; P Anderson; R Kiessling
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

7.  Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.

Authors:  K Kono; M E Ressing; R M Brandt; C J Melief; R K Potkul; B Andersson; M Petersson; W M Kast; R Kiessling
Journal:  Clin Cancer Res       Date:  1996-11       Impact factor: 12.531

8.  Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer.

Authors:  Evgeniy Eruslanov; Molly Neuberger; Irina Daurkin; George Q Perrin; Chester Algood; Philipp Dahm; Charles Rosser; Johannes Vieweg; Scott M Gilbert; Sergei Kusmartsev
Journal:  Int J Cancer       Date:  2011-06-21       Impact factor: 7.396

9.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Microenvironmental arginine depletion by macrophages in vivo.

Authors:  G A Currie; L Gyure; L Cifuentes
Journal:  Br J Cancer       Date:  1979-06       Impact factor: 7.640

View more
  36 in total

1.  Systemically delivered adipose stromal vascular fraction cells disseminate to peripheral artery walls and reduce vasomotor tone through a CD11b+ cell-dependent mechanism.

Authors:  Marvin E Morris; Jason E Beare; Robert M Reed; Jacob R Dale; Amanda J LeBlanc; Christina L Kaufman; Huaiyu Zheng; Chin K Ng; Stuart K Williams; James B Hoying
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

Review 2.  The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention.

Authors:  Joanna Domagala-Kulawik
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

4.  p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.

Authors:  Nicola R Hardwick; Mary Carroll; Teodora Kaltcheva; Dajun Qian; Dean Lim; Lucille Leong; Peiguo Chu; Joseph Kim; Joseph Chao; Marwan Fakih; Yun Yen; Jonathan Espenschied; Joshua D I Ellenhorn; Don J Diamond; Vincent Chung
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

5.  Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes.

Authors:  Sílvia Casacuberta-Serra; Marta Parés; Arantxa Golbano; Elisabet Coves; Carmen Espejo; Jordi Barquinero
Journal:  Immunol Cell Biol       Date:  2017-01-21       Impact factor: 5.126

6.  Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.

Authors:  Jihao Zhou; Yushi Yao; Qi Shen; Guoqiang Li; Lina Hu; Xinyou Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-20       Impact factor: 4.553

7.  Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Authors:  Trevor E Angell; Melissa G Lechner; Alison M Smith; Sue E Martin; Susan G Groshen; Dennis R Maceri; Peter A Singer; Alan L Epstein
Journal:  Thyroid       Date:  2016-02-10       Impact factor: 6.568

Review 8.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 9.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.